InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie

20 May 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals” or the “Company”) has today entered into a conditional agreement to acquire all shares in Flerie Invest AB. The acquisition is made through an issue in kind of 6,073,952,948 new shares in the Company, following which Flerie Invest AB’s shareholders will initially hold approximately 91.9 per cent of the shares and InDex Pharmaceuticals’ existing shareholders will initially hold approximately 8.1 per cent of the shares in the Company.

InDex Pharmaceuticals provides a status update and informs about Extraordinary General Meeting on June 10, 2024

May 6, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals” or the “Company”) announces that the evaluation of options for the future of the Company, including the reverse merger communicated in a press release on April 8, 2024 (the “Transaction”), is still ongoing. In a separate press release, the Board of Directors of InDex Pharmaceuticals convenes an Extraordinary General Meeting to be held on June 10, 2024.

InDex Pharmaceuticals provides a company update

8 April, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that the evaluation of alternatives for the Company´s future, as communicated in a press release on February 26, 2024, has been finalized and presented to the Board according to plan.

Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)

N.B. This English text is an unofficial translation of the Swedish original of the notice to attend the annual general meeting. In case of any discrepancies between the Swedish and English language versions, the Swedish version shall prevail

April 5 2024 – Shareholders in InDex Pharmaceuticals Holding AB, reg. nr 559067-6820 (the “Company”), are hereby summoned to the Annual General Meeting on Tuesday May 7, 2024 at 17.00 (CET) at Setterwalls Advokatbyrå’s offices at Sturegatan 10 in Stockholm. Registration for the meeting commences at 16.30 (CET).

CEO and CFO both to leave InDex Pharmaceuticals

March 26, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that CEO Jenny Sundqvist and CFO & Deputy CEO Johan Giléus will leave the company per September 26, 2024.

InDex Pharmaceuticals provides an update on company’s future

26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) announces that, in light of today’s separate press release, with the announcement that the development of cobitolimod is discontinued, the company is evaluating other alternatives to maximize shareholder value. Alternatives such as merger and reverse merger are weighed against company liquidation. InDex Pharmaceuticals will not proceed with development of any of its other compounds. 

InDex Pharmaceuticals discontinues the development of cobitolimod

26 February, 2024 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announced that the company will discontinue development of their drug candidate cobitolimod. Thorough analysis of the data from Induction Study 1 of the phase III program CONCLUDE has not provided any results justifying continued development.

Investor contact

Johan Giléus
Johan Giléus
+46 8 122 038 50